PDGFRB and neoplasm: Sorafenib is a commonly used multi-kinase inhibitor which inhibits the activity of Ser/Thr kinase Raf (which play a significant role in tumor cell proliferation or signaling) and angiogenesis-related receptor tyrosine kinases, VEGFR2 and PDGFR [28,49,50,51,52].